secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2024-04-03T23:59:59+00:00
Accession:  0001815776-24-000035
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LENZ Therapeutics: LNZ100 meets Phase 3 primary endpoint; 71% responder rate at 3 hours
--------------------------------------------------------------------------------

- Primary endpoint met: 71% of LNZ100 patients achieved ≥3-line improvement in near vision at 3 hours without distance loss (p<0.0001).
- Rapid onset: 71% achieved ≥3-line improvement at 30 minutes; long duration: 40% at 10 hours.
- No serious treatment-related adverse events in >30,000 treatment days across three trials.
- LNZ100 selected as lead candidate; company plans NDA submission to FDA in mid-2024.
- Patient survey: 90% reported near vision improvement; 75% would continue use post-study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000181577624000035/0001815776-24-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000181577624000035/lenz-20240403.htm
  HTML page:      https://secwatch.observer/filing/0001815776-24-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer